Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Teleflex Q3 revenue slightly beats estimates

Teleflex Q3 revenue slightly beats estimates

ReutersReuters2026/11/05 11:47


Overview

  • US medical device maker's Q3 revenue up 0.2% yr/yr, slightly beating analyst expectations

  • Adjusted diluted EPS for Q3 rose to $2.63, beating consensus

  • Company repurchased $350 mln in stock since July 1, 2026


Outlook

  • Teleflex maintains 2026 pro forma adjusted constant currency revenue growth guidance at 3.5%-4.5%

  • Company raises 2026 adjusted diluted EPS guidance to $7.50-$7.75 from continuing operations

  • Teleflex lowers 2026 GAAP revenue growth guidance to 13.2%-14.2% due to foreign exchange changes


Result Drivers

  • SEGMENT PERFORMANCE - Vascular and Surgical units delivered mid-single-digit growth, while Interventional returned to modest growth, per CEO Jason Weidman

  • TARIFF REFUNDS - Q3 results benefited from $16.5 mln in IEEPA tariff refunds recognized in continuing operations

  • MARGIN EXPANSION - Co cited margin expansion as contributing to robust EPS growth, even when excluding tariff refunds, per CEO Jason Weidman


Company press release: ID:nBwvY6jfa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$567.78 mln

$566.77 mln (11 Analysts)

Q3 Adjusted EPS

Beat

$2.63

$1.90 (12 Analysts)

Q3 EPS continuing operations

$1.30

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Teleflex Incorporated is $155.00, about 3.4% above its November 4 closing price of $149.87

  • The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago


Reuters Recommended Reads

  • Nov 4 - Insulet Q3 revenue beats estimates on strong Omnipod sales

  • Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices

  • Nov 4 - LivaNova Q3 revenue beats estimates on cardiopulmonary segment strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!